SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
ETFI Global Healthcare Sector PerformIdex
NVS
|
|
|
<> 
The accompanying table presents the top five rated companies with market caps of at least $250 million (USD) from each of the nine new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 400 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 45 top rated companies ranging from small-caps to mega-caps from the following underlying healthcare indexes:
1.) ETFI Global Hospitals – Fresenius Medical (FMS)
2.) <> ETFI New Drug Regulatory Catalys...
|
Teva Beats on Profits: A Biogeneric Boon in '09?
NVS
|
|
|
<> 
<> Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than dou...
|
My 60 Defensive Growth Stock Picks at Inner8.com
NVS
|
|
|
<> 
<> The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO), ...
|
Expanding Defensive Growth Index into Europe
NVS
|
|
|
<> 
<> The accompanying table presents an updated version of the ETFI Highly Defensive PerformIdex, which is expanded to 40 companies with market caps of at least $10B from the industry groups listed below. This defensive growth index is heavily weighted in consumer staples and healthcare and is now structured to include companies based in Europe, in addition to the United States and Canada.
Compared to the previous version, this index has a lower beta and higher average market cap and adds European companie...
|
A Waiting Game for Momenta Pharma
NVS
|
|
|
<> 
According to a SEC 8-K filing today, an amendment has been submitted to the FDA for Momenta Pharma's (MNTA) Enoxaparin Sodium Injection Abbreviated New Drug Application [ANDA] by its partner, Sandoz, which is the generic drug operating division of Novartis (NVS). Momenta believes the amendment represents a complete response to the agency's concerns over the potential for immune-mediated reactions to the product, which is intended to be a generic equivalent of the injectable blood thinner Lovenox.
Momenta Pharma represe...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Novartis AG
- Answers.com
